Go Pro

Bank of America Corp DE Cuts Holdings in DaVita Inc. $DVA

DaVita logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bank of America cut its DaVita stake by 33.4% in the first quarter, selling 120,642 shares and retaining 241,059 shares worth approximately $37.0 million. Other institutions increased holdings, with institutional investors collectively owning 90.12% of the stock.
  • Analysts have a consensus “Hold” rating on DaVita, with an average price target of $221.75; individual targets range from $215 to $270.
  • DaVita exceeded quarterly expectations, reporting $4.02 in EPS versus the $3.88 consensus and $3.55 billion in revenue, up 5.2% year over year. The company maintained fiscal 2026 EPS guidance of $14.10–$15.20.
  • MarketBeat previews the top five stocks to own by September 1st.

Bank of America Corp DE lowered its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 33.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,059 shares of the company's stock after selling 120,642 shares during the period. Bank of America Corp DE owned 0.38% of DaVita worth $37,048,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in DVA. Fifth Third Bancorp raised its position in DaVita by 831.4% during the 1st quarter. Fifth Third Bancorp now owns 38,411 shares of the company's stock worth $5,903,000 after buying an additional 34,287 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of DaVita by 27.4% during the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company's stock worth $32,627,000 after buying an additional 45,609 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its stake in DaVita by 63.5% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company's stock valued at $9,770,000 after purchasing an additional 33,394 shares during the last quarter. LSV Asset Management raised its stake in DaVita by 1.1% during the fourth quarter. LSV Asset Management now owns 936,768 shares of the company's stock worth $106,426,000 after purchasing an additional 9,739 shares during the period. Finally, M&T Bank Corp grew its holdings in shares of DaVita by 694.7% during the 4th quarter. M&T Bank Corp now owns 22,307 shares of the company's stock worth $2,534,000 after purchasing an additional 19,500 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on DVA shares. Oppenheimer set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $265.00 price target on shares of DaVita in a research note on Wednesday, August 5th. UBS Group raised their price objective on shares of DaVita from $235.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Truist Financial reduced their price objective on DaVita from $250.00 to $215.00 and set a "hold" rating for the company in a research report on Friday, August 7th. Finally, Barclays boosted their target price on shares of DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $221.75.

View Our Latest Stock Analysis on DaVita

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.90% of the stock is owned by insiders.

DaVita Stock Performance

Shares of DVA stock opened at $180.14 on Friday. The company has a market cap of $11.49 billion, a P/E ratio of 14.74, a PEG ratio of 0.60 and a beta of 0.88. The stock has a 50 day simple moving average of $217.34 and a two-hundred day simple moving average of $179.11. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company's revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

DaVita Company Profile

(Free Report)

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Featured Stories

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in DaVita Right Now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines